These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34144936)

  • 21. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Al-Salama ZT
    Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
    Pérez-Ruixo C; Pérez-Blanco JS; Chien C; Yu M; Ouellet D; Pérez-Ruixo JJ; Ackaert O
    Clin Pharmacokinet; 2020 Feb; 59(2):229-244. PubMed ID: 31432469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apalutamide: First Global Approval.
    Al-Salama ZT
    Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
    Zang Z; Wang Z; Chiong E
    Int J Urol; 2022 Jun; 29(6):541. PubMed ID: 35384091
    [No Abstract]   [Full Text] [Related]  

  • 29. The development of apalutamide for the treatment of prostate cancer.
    Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
    Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
    Katsuta M; Kimura T; Tashiro K; Murakami M; Hata K; Yanagisawa T; Onuma H; Yamamoto T; Sugaya S; Watanabe Y; Nobeyama Y; Egawa S; Asahina A
    Anticancer Res; 2022 Apr; 42(4):2023-2028. PubMed ID: 35347024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apalutamide for the treatment of prostate cancer.
    Rathkopf DE; Scher HI
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Apalutamide and Overall Survival in Non-metastatic Castration-resistant Prostate Cancer.
    van der Poel HG
    Eur Urol; 2020 Jul; 78(1):116-117. PubMed ID: 32173126
    [No Abstract]   [Full Text] [Related]  

  • 33. Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
    Yanai Y; Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jul; 19(1):720. PubMed ID: 31331293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
    Sasaki D; Hatakeyama S; Tanaka T; Okamoto T; Yoneyama T; Ohyama C
    Int J Urol; 2022 Jul; 29(7):772-773. PubMed ID: 35285092
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
    Pan A; Reingold RE; Zhao JL; Moy A; Kraehenbuehl L; Dranitsaris G; McBride SM; Scher HI; Kollmeier MA; Xiao H; Rathkopf DE; Lacouture ME
    J Urol; 2022 May; 207(5):1010-1019. PubMed ID: 35020444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
    Saad F; Chi KN; Shore ND; Graff JN; Posadas EM; Lattouf JB; Espina BM; Zhu E; Yu A; Hazra A; De Meulder M; Mamidi RNVS; Bradic B; Francis P; Hayreh V; Rezazadeh Kalebasty A
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):25-37. PubMed ID: 33754187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
    Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.
    Nieto-Gómez P; Ubago-Pérez R; Cabeza-Barrera J
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):355-363. PubMed ID: 31133348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2019 Oct; 202(4):661. PubMed ID: 31294666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.